MicroRNA-155 Controls Exosome Synthesis and Promotes Gemcitabine Resistance in Pancreatic Ductal Adenocarcinoma

The cancer drug gemcitabine (GEM) is a key drug for treating pancreatic ductal adenocarcinoma (PDAC), but PDAC cells develop chemoresistance after long-term administration. Since the tolerance was immediately spread to every PDAC tissue in a patient, it is assumed that some certain efficient mechani...

Descripción completa

Detalles Bibliográficos
Autores principales: Mikamori, Manabu, Yamada, Daisaku, Eguchi, Hidetoshi, Hasegawa, Shinichiro, Kishimoto, Tomoya, Tomimaru, Yoshito, Asaoka, Tadafumi, Noda, Takehiro, Wada, Hiroshi, Kawamoto, Koichi, Gotoh, Kunihito, Takeda, Yutaka, Tanemura, Masahiro, Mori, Masaki, Doki, Yuichiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5309735/
https://www.ncbi.nlm.nih.gov/pubmed/28198398
http://dx.doi.org/10.1038/srep42339

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5309735/
https://www.ncbi.nlm.nih.gov/pubmed/28198398
http://dx.doi.org/10.1038/srep42339

Ejemplares similares